Cellular and Molecular Changes of Brain Metastases-Associated Myeloid Cells during Disease Progression and Therapeutic Response

Michael Schulz, Birgitta Michels, Katja Niesel, Stefan Stein, Henner Farin, Franz Rödel, Lisa Sevenich

sevenich@gsh.uni-frankfurt.de

HIGHLIGHTS
Tumor education gene signatures arise early during tumor onset and remain stable
TAM-MG and TAM-MDM induce distinct genetic programs in response to tumor education
Radiotherapy enhances the influx of blood-borne myeloid cells
Radiotherapy transiently reverses tumor education signatures in TAM-MDM

Schulz et al., iScience 23, 101178 June 26, 2020 © 2020 The Author(s).
https://doi.org/10.1016/j.isci.2020.101178
Cellular and Molecular Changes of Brain Metastases-Associated Myeloid Cells during Disease Progression and Therapeutic Response

Michael Schulz, Birgitta Michels, Katja Niesel, Stefan Stein, Henner Farin, Franz Rödel, and Lisa Sevenich

SUMMARY
Brain-resident microglia and bone marrow-derived macrophages represent the most abundant non-cancerous cells in the brain tumor microenvironment with critical functions in disease progression and therapeutic response. To date, little is known about genetic programs that drive disease-associated phenotypes of microglia and macrophages in brain metastases. Here, we used cytometric and transcriptomic analyses to define cellular and molecular changes of the myeloid compartment at distinct stages of brain metastasis and in response to radiotherapy. We demonstrate that genetic programming of tumor education in myeloid cells occurs early during metastatic onset and remains stable throughout tumor progression. Bulk and single cell RNA sequencing revealed distinct gene signatures in brain-resident microglia and blood-borne monocytes/macrophages during brain metastasis and in response to therapeutic intervention. Our data provide a framework for understanding the functional heterogeneity of brain metastasis-associated myeloid cells based on their origin.

INTRODUCTION
Brain metastases (BrM) represent the most common intracranial tumor in adults and affect approximately 20%-40% of all patients with cancer. Patients with melanoma and breast and lung cancer show the highest incidence (Ostrom et al., 2018; Stelzer, 2013; Tabouret et al., 2012). Owing to improved management of the localized primary disease, numbers of patients with cancer who develop BrM are increasing (Tabouret et al., 2012). The development of BrM is associated with poor patient prognosis and limited efficacy of standard of care as well as targeted- or immunotherapies (Kalsi et al., 2015; Valiente et al., 2018). In addition to tumor cell intrinsic traits, effects of the tumor microenvironment (TME) are known to affect tumor progression and significantly contribute to therapy resistance (Quail and Joyce, 2013; Schulz et al., 2019). The brain represents a unique tissue environment harboring a range of specialized cell types including neurons and neuroglia (Jakel and Dimou, 2017; Zeng and Sanes, 2017). Detailed insight into the cellular composition of the immune landscape of the central nervous system (CNS) has recently led to a paradigm shift challenging the traditional view of the CNS as an immune privileged organ (Mrdjen et al., 2018). The presence of innate and adoptive immune cells within border-associated regions including the meninges, choroid plexus, and perivascular space suggest their active involvement in CNS immunity. In contrast to the highly specialized areas of the brain that represent an interface between the CNS and the systemic immune system, yolk sac-derived microglia represent the major immune cell type in the brain parenchyma with critical roles in immune surveillance, host defense, and housekeeping functions such as synaptic pruning (Butovsky and Weiner, 2018; Hagemeyer et al., 2017; Norris and Kipnis, 2019; Paolicelli et al., 2011). A series of studies shed further light onto the heterogeneity of distinct microglial subsets and border-associated macrophages (BAMs) within different homeostatic states (Masuda et al., 2019; Thion et al., 2018; Utz et al., 2020) or disease conditions (Keren-Shaul et al., 2017; Krasemann et al., 2017; Mathys et al., 2017; Tay et al., 2018). Large-scale transcriptomic analyses of microglia and BAMs in neurodegenerative disorders and neuroinflammation demonstrated a striking similarity of gene signatures across different malignancies. Microglia that acquire a distinctive molecular activation signature have recently been denoted as “disease-associated microglia” (DAM) (Keren-Shaul et al., 2017) or “microglia neurodegenerative phenotype” (MgND) (Krasemann et al., 2017). The overlap of gene signatures within DAMs from different neurodegenerative or neuroinflammatory conditions suggests that genetic programs defining the switch from
Figure 1. Cellular Composition of the Tumor Microenvironment of H2030-BrM
(A) Schematic overview of the experimental design and methodology.
(B) Representative immunofluorescence images of tumor-free control brain and small and large metastatic lesions in the H2030-BrM model stained with indicated markers. Scale bar, 200 μm.
(C) Representative immunofluorescence image of a brain metastatic lesion and adjacent normal brain parenchyma stained for Iba1 and Tmem119. Dotted line depicts the tumor margin. Overview is split into Iba1 staining (left panel) and an overlay of Iba1 and TMEM119 staining (right panel). Scale bar, 100 μm.

Figure 1. Cellular Composition of the Tumor Microenvironment of H2030-BrM
(A) Schematic overview of the experimental design and methodology.
(B) Representative immunofluorescence images of tumor-free control brain and small and large metastatic lesions in the H2030-BrM model stained with indicated markers. Scale bar, 200 μm.
(C) Representative immunofluorescence image of a brain metastatic lesion and adjacent normal brain parenchyma stained for Iba1 and Tmem119. Dotted line depicts the tumor margin. Overview is split into Iba1 staining (left panel) and an overlay of Iba1 and TMEM119 staining (right panel). Scale bar, 100 μm.
homeostatic to disease-associated phenotypes might represent a general microglial priming or sensing of pathogen-associated pattern rather than unique responses to specific stimuli (Deczkowska et al., 2018).

Single cell analyses of neurodegenerative disorders (e.g., Huntington disease, HD) in comparison with neuroinflammatory conditions such as different stages of experimental autoimmune encephalomyelitis (EAE) revealed that disease-associated myeloid cells are predominately derived from microglia pools, whereas recruitment of monocyte populations is almost completely absent in HD and occurs at relatively low rates (below 5%–10%) during the course of EAE (Ajami et al., 2018). In contrast, the presence of brain tumors induces significant recruitment of myeloid cells from the peripheral immune system including inflammatory monocytes, monocyte-derived macrophages (MDMs), and granulocytes. In glioma models, MDMs constitute up to 50%–75% of the of tumor-associated macrophages (TAMs) population (Bowman et al., 2016; Chen et al., 2017). Given the technological challenges to discriminate TAMs derived from brain-resident microglia from recruited MDM controversy remained on the functional contribution of each subpopulation based on their origin. The use of lineage tracing models and the identification of cell type-restricted markers allowed the evaluation of disease-associated roles of macrophages and microglia in brain malignancies. Intriguingly, analyses of the molecular identity of TAMs in glioma likewise suggest the induction of disease-associated signatures (Bowman et al., 2016). Functional annotation revealed that microglia-derived TAMs (TAM-MG) display signatures associated with pro-inflammatory responses, host defense mechanisms, and synaptic pruning. In contrast, gene signatures identified in monocyte-derived macrophages (TAM-MDM) in glioma were associated with immune suppression, antigen presentation, and wound healing (Bowman et al., 2016).

However, to date little is known about the functional contribution of TAM-MG and TAM-MDM in BrM. Here, we characterized the myeloid cell compartment in a lung-to-brain metastases model to investigate cellular and molecular changes during tumor progression and in response to radiotherapy. We demonstrate that BrM-induced TAM programming occurs early during metastatic colonization and remains stable during tumor progression. Application of radiotherapy has the potential to transiently reverse tumor education signatures in TAMs in BrM.

RESULTS

Cellular Composition of the Tumor Microenvironment in Brain Metastases

We first analyzed changes of the cellular composition of the TME in the xenograft lung-to-brain metastasis model H2030 (Nguyen et al., 2009) (Figure 1A, S1A, and S1B) following metastatic seeding and outgrowth. Histological assessment of distinct stages of brain metastasis (BrM) revealed that early-stage metastases induce the recruitment and activation of glial cells including astrocytes and microglia (Lorger and Felding-Habermann, 2010; Valiente et al., 2014). Astrogliosis remains prominent at later stages with GFAP+ reactive astrocytes forming a glial scar that delineates the tumor from the brain parenchyma (Figure 1B, left panel). Astrocytes are located at the tumor-stroma interface, whereas tumor-associated macrophages/microglia (TAMs) infiltrate into BrM lesions (Figure 1B). TAMs in close vicinity to tumor cells show strong induction of Iba1 expression and a morphological change from a ramified phenotype typical for resting microglia toward an ameboid morphology of activated microglia (Figure 1C, left). Co-staining with the microglia marker Tmem119 (Bennett et al., 2016) showed Tmem119+/Iba1+ cells in the adjacent brain parenchyma, whereas Tmem119+/Iba1+ as well as Tmem119-/Iba1+ TAMs are present within the tumor lesion indicating the infiltration of monocyte-derived macrophages (MDMs) (Figure 1C, right) and/or a downregulation of the expression of homeostatic microglia marker in TAMs as previously observed in the context of different brain malignancies (Jordao et al., 2019; Keren-Shaul et al., 2017; Sankowski et al., 2019). Other brain resident cell types such as neurons are rather displaced by the growing tumor (Seano et al., 2019) and do not infiltrate BrM lesions (Figure 1B, middle panel). Upon extravasation, H2030-BrM tumors grow along pre-existing blood vessels (Figure 1B, right panel). However, the vasculature within large H2030-BrM lesions is abnormal with highly irregular and enlarged vessels (Figure 1B) and hemorrhages are frequently observed in H2030-BrM (Figure S1A) indicating a leaky blood-tumor barrier (BTB).
Peripheral Monocyte-Derived Cells Contribute to the Myeloid Compartment in Lung-to-Brain Metastases

To gain further insight into the dynamics of the recruitment from the periphery and the cellular identity of blood-borne immune cells in BrM, we analyzed the myeloid cell compartment at distinct stages of tumor progression by flow cytometry. Given the previous observation that microglia and blood-borne monocytes/macrophages associated to different CNS pathologies show assimilation of microglial marker expression including P2ry12 and Tmem119, we employed an alternative gating strategy to discriminate brain-resident microglia and macrophages (MDMs) based on CD49d expression as previously described (Bowman et al., 2016). We focused our analysis on the four most abundant myeloid immune cell populations in BrM, namely, inflammatory monocytes (CD45+CD11b+Ly6C<sup>high</sup>Ly6G<sup>-</sup>; TA-Mono), granulocytes (CD45<sup>-</sup>CD11b<sup>-</sup>Ly6C<sup>mwm</sup>Ly6G<sup>high</sup>; TA-Granu), MDM (CD45<sup>-</sup>CD11b<sup>-</sup>Ly6C<sup>low</sup>Ly6G<sup>-</sup>CD49d<sup>-</sup>; TAM-MDM), and microglia (CD45<sup>-</sup>CD11b<sup>-</sup>Ly6C<sup>mwm</sup>Ly6G<sup>-</sup>CD49d<sup>-</sup>; TAM-MG) (Figure S1D). BrM-bearing mice were stratified into mice with small and large lesions based on bioluminescent intensity (BLI) with a mean BLI output of 4x10<sup>7</sup> photons x sec<sup>-1</sup> (ranging from 3x10<sup>5</sup> to 7.5x10<sup>7</sup> photons x sec<sup>-1</sup>) or 2.15x10<sup>8</sup> photons x sec<sup>-1</sup> (ranging from 1x10<sup>8</sup> to 5.3x10<sup>8</sup> photons x sec<sup>-1</sup>), respectively. Flow cytometry of macro-dissected BrM lesions revealed continuous infiltration of inflammatory monocytes, granulocytes, and MDMs during tumor progression compared with tumor-free control mice that only showed minimal amounts of non-microglial myeloid cells (Figure 1D). TAMs constitute the largest cell population within the myeloid cell compartment comprising 85% and 75% of the CD45+CD11b+ cell population in small and large BrM lesions, respectively (Figure 1D). In small BrM lesions, only 10% of the TAM population was derived from MDM (TAM-MDM), whereas the remaining 90% originated from brain-resident, yolk sac-derived microglia (TAM-MG) (Figure 1D). An increase of the TAM-MDM population to approximately 20% of the TAM population was observed in large BrM lesions (Figure 1D). This increase is likely due to influx from the periphery rather than local proliferation of TAMs in BrM lesions given the low percentage of Ki67+Iba1+ cells that are present in the tumor core and at the tumor-stroma interface (Figure S1C). We did not observe differences in the amount of Ki67+Iba1+ cells depending on the tumor size. Next, we analyzed the secretome from the H2030-BrM cell line to identify factors that are implicated in the recruitment and activation of TAMs using a multiplex assay. We found a range of chemokines in tumor cell-conditioned media from H2030-BrM cells that were previously associated to monocyte/macrophage recruitment including CCL2, CCL4, CCL5, and CXCL10 (Shi and Pamer, 2011) and cytokines with known roles in macrophage polarization/activation including the interleukins (IL)-4, IL-6, IL-8, IL-17, as well as VEGF, IFN-β, TNF-α, and GM-CSF (Palma et al., 2018) (Figure 1E).

Tumor Education Induces Distinct Inflammatory Gene Signatures in Myeloid Cells

Next, we purified myeloid cells by fluorescence-activated cell sorting (FACS) for RNA sequencing (RNA-seq) analysis to gain insight into the molecular identity of different BrM-associated myeloid subpopulations. The purity of the sorted cell populations was validated by the expression of cell type-restricted markers for each population based on RNA-seq data (Figure S1E). Principal component analysis (PCA) of BrM-associated cells (TAM-MG, TAM-MDM, and TA-Mono) and their respective normal cellular counterparts (normal microglia from tumor-free brain [N-MG] and blood monocytes [N-Mono]) revealed distinct cell type-specific clustering (Figure 1F, Table S1). Surprisingly, we did not observe major changes in gene expression depending on the tumor stage with only a few differentially expressed genes (DEGs) in distinct BrM stages (small versus large BrM-associated cells; Figures 1F and 1G, Table S1). Among the four analyzed tumor-associated myeloid cell populations, granulocytes segregated most strongly from the remaining populations, whereas monocytes and macrophages clustered closely together but clearly separated from microglia (Figure S1F). Granulocytes displayed the highest variation in gene expression depending on the tumor stage with 21 DEGs, whereas TA-Mono and TAM-MDM only showed 8 and 7 DEGs, respectively. The lowest impact of tumor progression was found in TAM-MG with only 2 DEGs between small and large BrM lesions (Figure 1G, Table S1). In summary, our data indicate that metastatic colonization induces disease-associated transcriptional profiles in myeloid subpopulations that significantly differ from genetic programs of their normal cellular counterparts. Each BrM-associated myeloid cell population clustered separately indicating the maintenance of lineage-specific gene signatures despite their recruitment to the brain and education by metastatic tumor cells. Strikingly, transcriptional profiles induced by tumor education within the myeloid compartment occurred at early stages of metastatic colonization and remained stable during tumor progression.
Figure 2. Tumor Education Signatures of TAMs in BrM

(A) Euler diagrams depict the number of unique and shared upregulated (left panel) or downregulated (right panel) DEGs in control versus TAM-MG, or TAM-MDM, or TA-Mono.

(B–D) Volcano plot of control cells versus BrM-associated cells in (B) microglia, (C) MDM, and (D) monocytes. Cutoffs: ± 1 log2 fold change and adjusted p value <0.05.

(E–G) Functional gene annotation of altered cellular pathways in (E) TAM-MG, (F) TAM-MDM, and (G) TA-Mono compared with control cell types from tumor-free animals. Cutoffs: ± 1 log2 fold change and adjusted p value <0.05. All DEGs or top 3,000 DEGs based on adjusted p values were subjected to analysis.

(H–J) Unsupervised clustering of the top 50 DEGs in control versus BrM-associated (small and large stage) TAMs for (H) microglia, (I) MDM, and (J) monocytes. n = 4–5 replicates for each condition.

Origin of TAMs Affects Transcriptional Profiles Associated with Tumor Education in Brain Metastases

To evaluate whether TAMs in BrM show differences in their transcriptomes depending on their origin (bone marrow derived versus yolk sac derived), we analyzed gene expression in TA-Mono, TAM-MDM, and TAM-MG compared with their respective normal counterparts. This analysis revealed a total of 3,279 upregulated and 26,175 downregulated genes in tumor-associated myeloid cells compared with control conditions across all analyzed cell types (Figure 2A). The majority of DEGs were unique for each cell type. By comparison, TA-Mono and TAM-MDM shared a higher number of common DEGs than TAM-MG with TA-Mono or TAM-MDM. Moreover, we identified 239 and 777 genes that were up- or downregulated in all three cell types compared with normal controls (Figures 2A and S2A). Among the DEGs that were concomitantly upregulated in all analyzed BrM-associated myeloid populations, we found several key regulators of CNS inflammation including Axl, Il1b, C3ar1, and Apoe (Figures 2B–2D and S2A) (Albulescu et al., 2013; Bouwens van der Vlis et al., 2018; Krasemann et al., 2017; Ray et al., 2017). Although the gene signatures revealed a considerable overlap of DEGs, our data also indicated the induction of different modes of inflammation in brain-resident versus recruited TAM populations. Several DEGs in TAM-MG were associated with type-1 interferon signaling (e.g., Irf7) different modes of inflammation in brain-resident versus recruited TAM populations. Several DEGs in TAM-MG from H2030-BrM revealed striking similarities to previously described DAM markers (Keren-Shaul et al., 2017) (Figures S3A and S3B), further supporting the hypothesis that different pathological stimuli induce similar core signatures in disease-associated microglia (Deczkowska et al., 2018). Moreover, we observed down-regulation of homeostatic marker, including Cx3cr1, P2ry12, and Tmem119 (Figures 2B and S3A), as previously demonstrated for disease-associated microglia in neurodegenerative disorders and brain cancer (Jordao et al., 2019; Keren-Shaul et al., 2017; Sankowski et al., 2019), as well as upregulation of those markers in TAM-MDM (Figure S3A). In contrast, genes involved in antigen presentation as well as responses to hypoxia and induction of angiogenesis were induced in TAM-MDM and TA-Mono (Figures 2C and 2D). Gene expression changes were further validated by qRT-PCR for each cell type (Figures S2B–S2D). Functional annotation of the DEGs identified in TAMs confirmed that TAM-MG, TAM-MDM, and TA-Mono collectively induce inflammatory responses, whereas the loss of housekeeping functions was predominately represented in the TAM-MG population with four of five gene ontology (GO) terms being related to CNS processes (Figures 2E–2G). The induction of different modes of inflammatory responses was further supported by the analysis of the 50 most differentially expressed genes. Unsupervised clustering revealed that TAM-MG show a high representation of genes that are associated with innate immune sensing and host defense mechanism including chemokines (e.g., Cxcl13, Cxcl16), components of the complement cascade (e.g., C3, C4b), Toll-like receptor signaling (Tlr2), and Tyro-Axl-Mer receptor signaling (Axl) (Figure 2H). In contrast, we identified gene signatures in TAM-MDM that are rather associated with antigen presentation and adaptive immunity (H2-Eb1, H2-Oa, Cd83, Cd86) as well as alternative macrophage activation (Ms4a7, Mrc1) known to be involved in wound healing and tumor promotion (Figures 2F and 2I). TA-Mono displayed a considerable overlap of DEGs with TAM-MDM (Figures 2A, 2G, and 2J).

Given the enrichment of complement cascade components in TAM-MG in response to tumor activation, we queried our dataset for the expression of a range of members. We observed a significant induction of gene expression for the majority of analyzed complement components indicating that activation of the complement cascade represents a central pathway in instigating an inflammatory response upon interaction with cancer cells (Figures 3A and 3B). Since central mediators of the complement cascade act paracrine, it is not surprising that on protein level distinct complement components were present at the interface of Iba1+ and H2030 tumor cells (Figure 3C). Interestingly, we found the complement inhibitor Factor H in tumor cells in close vicinity to Iba1+ TAMs, indicating a protective mechanism to block complement-mediated anti-tumor responses (Figure 3C). Another protective mechanism of tumor cells that we observed in H2030-BrM is
the expression of the “don’t eat me-signal” CD47 (Figure S4A) that protects cells from phagocytic uptake and is likely induced in response to extracellular TNF-α (Betancur et al., 2017). Based on our RNA-seq and cytokine array data, TAMs (Figure S4B) as well as tumor cells (Figure 1E) represent a potential source for TNF-α expression in H2030-BrM. Similar to the induction of complement cascade components, we noticed a high representation of solute carrier (Slc) family members among the 500 most differentially expressed genes in TAM-MG (Figure S5A). The Slc family comprises a range of different transporters with known roles in regulating cellular physiology (Lin et al., 2015). Interestingly, we found 66 genes that belong to the Slc family to be differentially expressed in TAM-MG isolated from small and large BrM compared with N-MG indicating that the acquisition of the tumor-educated phenotype requires a profound modulation of the cellular machinery regulating the sensing and transport of nutrients and metabolites suggesting altered energy consumption by TAM-MG.

Based on our results that TAM-MDM display characteristics of alternative activation, we next queried the expression of a range of markers to evaluate activation/polarization states of TAM-MDM and TAM-MG in small and large BrM lesions. We chose markers associated to key macrophage functions including inflammatory pathways, phagocytosis, and chemotaxis. Among the analyzed markers (M1-like = 19 genes, left panel and M2-like = 13 genes, right panel) we found several to be significantly induced in distinct stages of tumor progression in TAM-MG and TAM-MDM indicating a mixed activation/polarization state rather than the acquisition of an M1-like or M2-like phenotype in TAMs (Figure 3D). Interestingly, we observed that TAM-MG rather induced expression of markers associated with pro-inflammatory (M1-like) phenotypes (e.g., Ccl2, Ccl3, Ccl4, Ccl5, Ifnb1, Il12b, Tlr2, Tlr4, Tnf), whereas markers of alternative activation (M2-like) were induced in TAM-MDM (e.g., Ccl17, Ccl22, Cdf163, Tlr1) (Figure 3D). Collectively, our data indicate that TAM-MG in H2030-BrM induce transcriptional states associated with host defense mechanisms, whereas TAM-MDM rather display signatures of antigen presentation and wound healing.

In summary, our data reveal that lung-to-brain metastases induce distinct disease-associated transcriptional programs in TAM-MG and TAM-MDM suggesting non-redundant functions in tumor progression. To further interrogate cellular responses of TAM-MG and TAM-MDM upon different stimuli, we extended our analysis to effects of therapeutic intervention on TAM phenotypes. Given recent reports on immune modulatory functions of ionizing radiation (IR) (Vanpouille-Box et al., 2017; Wilkins et al., 2019) and the significance of radiotherapy as standard of care for patients with brain metastases (Suh et al., 2020), we next asked how therapeutic intervention would modulate tumor-associated inflammation in BrM.

**Fractionated Whole-Brain Radiotherapy of Lung Cancer-BrM-Bearing Mice Enhances Infiltration of Myeloid Cells**

IR was applied as fractionated whole-brain radiotherapy (WBRT) with 2 Gy on 5 consecutive days (5 × 2 Gy WBRT) or as one single dose of 10 Gy (1 × 10 Gy) in 1 arc using the Small Animal Radiation Research Platform (SARRP) (Wong et al., 2008) (Figure 4A) as previously described (Chae et al., 2019). Histological assessment of Iba1+ macrophages indicated an increase in the number of TAMs in response to WBRT (Figure 4B). To distinguish general effects of IR on myeloid cell infiltration into the CNS from tumor-induced effects, we analyzed the amount of blood-borne immune cells in tumor-free brains at d3 and d5 after IR compared with non-irradiated mice by flow cytometry (Figure 4C). This analysis revealed that IR with the chosen dosage and fractionation alone does not induce influx of peripheral immune cells into the brain in the absence of BrM (Figure 4C). In contrast, we observed a continuous increase in the infiltration of blood-borne myeloid cells over time after WBRT in BrM-bearing mice (Figure 4C). Infiltration of granulocytes and inflammatory monocytes peaked at d5 after fractionated WBRT with a relative decrease of the granulocytes and inflammatory monocyte content at d10 after WBRT, due to an expansion of the macrophage population.
between d3 and d10 after WBRT (Figure 4C). Interestingly, application of WBRT as one single dose of 1 × 10 Gy resulted in diminution of the TAM-MDM population at d3 after WBRT compared with 5 × 2 Gy but showed less prominent effects on the other BrM-associated myeloid populations. In summary, our data show that different IR regimens regulate the influx or ablation of blood-borne myeloid cells in BrM in a time- and dose-dependent manner supporting its applicability as an immune modulatory agent.

**WBRT Induces Transcriptomic Changes in BrM-Associated Myeloid Cells**

To evaluate the effects of WBRT on transcriptional profiles of H2030-BrM-associated myeloid cells, we performed RNA-seq on FACS-purified cell populations at distinct time points after WBRT (Figure 4A). PCA analysis across all samples from BrM revealed that clustering was mostly driven by cell type with no pronounced sub-clustering based on tumor size or in response to treatment at different time points (Figure 4D). This effect was also evident in the comparison of the number of DEGs that were identified in the analysis of untreated large BrM and BrM with IR (Figure 4E). Interestingly, for TAM-MG, TA-Mono, and TA-Granu we found the highest amount of DEGs in response to 1 × 10 Gy compared with 5 × 2 Gy WBRT, whereas this effect was inversely in the case of TAM-MDM (Figure 4E). Moreover, we only observed few common DEGs shared between different cell types by comparing all non-irradiated versus all irradiated (5 × 2 Gy) samples (Figure 4F) indicating high heterogeneity in cellular responses upon IR in different cell types (Table S2).

To further investigate cell type-specific radio-responses, we focused our analysis on the most abundant myeloid cells in BrM, TAM-MG, and TAM-MDM. Unsupervised clustering of the top 50 DEGs in TAM-MG and TAM-MDM at d3 and d10 after 5 × 2 Gy WBRT revealed cell type- and time point-dependent changes in their transcriptomes (Figure 5A). In TAM-MG, we predominately observed induction of transcription profiles at d3 after WBRT that are associated with an immediate danger response to cytotoxic effects of ionizing radiation (Figure 5A). At d10 after IR, not only danger responses are still evident in TAM-MG but also innate immune responses that we observed in response to tumor activation emerge (Figure 5A). In contrast, we found a loss of tumor education signatures in TAM-MDM at d3 after WBRT, followed by induction of immune effector processes and inflammatory responses (e.g., IFN type-1 responses) at d10 after WBRT (Figure 5A). We next sought to compare effects of conventionally fractionated (5 × 2 Gy) to one single dose of WBRT (1 × 10 Gy) on myeloid cells in BrM to evaluate potential dose-dependent differences in immune modulation (Figures 5B and S5B–S5E). Functional annotation of combined DEGs of all TAMs isolated from mice 3 days after 1 × 10 Gy and 5 × 2 Gy WBRT revealed the induction of stress response pathways upon DNA damage or oxidative stress in both experimental settings. Single application of 10 Gy led to a further induction of host defense mechanisms (Figure 5B). Interestingly, although 1 × 10 Gy WBRT led to an overall lower amount of peripheral myeloid cells at 3 days after IR, effects on gene signatures were more pronounced in response to single high doses (Figure 4E) and functional annotation across all four analyzed cell types suggests a more efficient induction of pro-inflammatory host defense responses (Figure 5B). To further evaluate the extent of IR-mediated modulation of transcriptional states of TAM-MG and TAM-MDM, we compared the number of DEG in each cell type in response to the different stimuli analyzed in this study. This comparison illustrated the dominant effect of tumor education of BrM-associated TAMs compared with tumor-naïve cell types, whereas effects of tumor progression from small to large lesions are insignificant in both cell types. Effects of IR are evident in both TAM populations; however, they are less pronounced than effects of tumor education (Figure 5C). Interestingly, the relative amount of DEGs in TAM-MG in response to IR is higher than in TAM-MDM (Figure 5C). This effect is most likely due to the...
Figure 5. Effects of Whole-Brain Radiotherapy on Distinct TAM populations in BrM

(A) Unsupervised hierarchical clustering heatmaps depicting Top 50 DEGs in TAM-MG (upper panel) and TAM-MDM (lower panel) of large stage BrM (each n = 4) versus d3 (left, both cell types n = 4) or d10 (right, both cell types n = 3), respectively.

(B) Top five functional gene annotation of DEG in the indicated conditions (cutoff: BM > 20, adj. p value < 0.05; log2 fold change).

(C) Pie chart depicting the amount of significantly DEGs in different comparisons of distinct MG or MDM conditions, reflecting BrM onset, progression, and radiotherapy, respectively. Cutoffs: BM > 20, adj. p value < 0.05. n = 3–5 per condition.
fact that the entire TAM-MG population is exposed to IR, whereas the TAM-MDM population is constantly replenished by newly recruited cells that have not directly been exposed to IR. Consequently, the TAM-MDM population is expected to show higher heterogeneity than TAM-MG.

**Single-Cell RNA-Seq Reveals Cellular Heterogeneity within Individual TAM Populations and in Response to IR**

To further explore the heterogeneity of TAM populations in H2030-BrM under treatment-naive conditions and in response to WBRT, we performed single-cell RNA-seq of index-sorted cells (Figure 6A). Combined tSNE analysis revealed the existence of 16 discrete clusters across all conditions (Figures 6B–6D). We observed an overall lower contribution of untreated and irradiated TAM-MG to the individual clusters indicating that TAM-MG represent a more homogeneous population compared with TAM-MDM (Figures 6B–6D). Although TAM-MG were found predominantly in cluster 9 (TAM-MG; no WBRT) and cluster 14 (TAM-MG; 5 × 2 Gy/d3), clustering of TAM-MDM spread across more clusters (Figure 6D) suggesting a higher cellular heterogeneity within the TAM-MDM population. Interestingly, we detected only minimal overlap between untreated TAM-MG and TAM-MDM, whereas irradiated TAM-MG and TAM-MDM were found in overlapping clusters (i.e., cluster 10, 14, and 15) thus likely reflecting shared radio-response states (Figures 6D, S6D, and S6E). The three clusters, however, showed only little overlap of similarly regulated genes. For example, clusters 14 and 15 revealed upregulation of *Lyz1* and *Lyz2*, whereas *Cd74* was downregulated in clusters 10, 14, and 15.

We further explored the expression of the 10 most differently expressed genes in TAM-MG versus TAM-MDM (Figures 6E–6H). In line with our bulk RNA-seq data, we observed high expression of pro-inflammatory mediators in TAM-MG including *Cxc13*, *Ccl3*, *Ccl4*, and *C1qb* as well as the microglial marker *Tmem119* and *Hexb* (Figures 6E and 6F). In contrast to the pro-inflammatory signature found in TAM-MG, scRNA-seq data further pointed toward the involvement of TAM-MDM in antigen presentation (e.g., *Cd74*, *H2-Aa*, *H2-Ab1*, *H2-Eb1*) (Figures 6G and 6H). Functional annotation of DEGs further supported transcriptional dichotomy of TAM-MG and TAM-MDM in H2030-BrM across different clusters (Figures 6I, 6J, and S6C). Moreover, we observed the presence of three additional clusters (clusters 3, 5, and 6) that segregated from the main TAM populations and were largely represented by untreated TAM-MDM (Figures 6B–6D). Although the identity of cells in clusters 3, 5, and 6 remains elusive, the respective clusters might represent either border-associated macrophages (BAMs) or migratory dendritic cells (migDCs) (Van Hove et al., 2019). Especially, genes highly expressed in cluster 6 (*Ccr7*, *Fscn*, *Socs2*, *Tmem123*) showed a considerable overlap of enriched genes previously shown for migDC (Figure S6D).

Taken together, data from the scRNA-seq analyses support our findings from bulk RNA-seq and independently confirm cell type-specific transcriptional states of TAM-MG and TAM-MDM. Importantly, scRNA-seq illustrated heterogeneity in the individual cell populations and supported our hypothesis that TAM-MG represent a more homogeneous population than TAM-MDM likely due to differences in the population turnover rates. Our data underpin the applicability of IR as an immune modulatory agent that can be used to transiently revert the immunosuppressive milieu in BrM by the recruitment of naive inflammatory cells that replenish the pool of tumor-educated TAM-MDM.

**DISCUSSION**

TAMs represent an integral part of the TME in many different cancer types. Owing to their high functional plasticity, it is not surprising that known TAM functions can range from anti-tumor activity to tumor promotion in a cancer type- and stage-dependent manner (Cassetta and Pollard, 2018; Yang et al., 2018). Recent
studies shed further light onto the functional diversity of TAMs in brain cancers based on their ontogenetic origin as yolk sac-derived microglia or bone marrow-derived macrophages (Bowman et al., 2016; Chen et al., 2017). However, to date a detailed characterization of the myeloid immune landscape in BrM is lacking. Here we used bulk and single-cell RNA-seq to dissect the molecular identity of the myeloid cell compartment in different stages of lung-to-brain metastasis and in response to radiotherapy. Although BrM recruit lower percentages of myeloid cells from the periphery compared with glioma, we observed a striking similarity of tumor-associated gene signatures of TAMs. In both glioma and BrM, a functional dichotomy was observed with TAM-MG being associated with host defense mechanisms and housekeeping functions such as synaptic pruning, whereas TAM-MDM are implicated in antigen presentation, immune suppression, and wound healing processes (Bowman et al., 2016). Given the central role of TAMs in regulating tumor progression, targeted therapies are emerging as a tool to disrupt tumor-promoting TAM functions. Current strategies often rely on the blockade of central macrophage differentiation and survival pathways such as CSF1R signaling (Pyonteck et al., 2013; Quail et al., 2016). Pre-clinical testing confirmed the efficacy of TAM-targeted therapies against different tumor types including brain cancers as mono-therapies and in combination with standard of care (Pyonteck et al., 2013; Quail et al., 2016; Stafford et al., 2016). However, a major limitation arises from the inability of those approaches to selectively target tumor promoting TAM populations while preserving physiologically critical functions. Analyses of tumor education gene signatures in TAM-MG and TAM-MDM in BrM presented herein provide a comprehensive resource to identify potential candidates as molecular targets for future functional validation and pre-clinical testing. In this regard two strategies appear most feasible: (1) TAM-MDM-directed strategies to block immune suppression and tumor promoting wound healing processes and (2) TAM-MG-directed approaches to maintain or induce pro-inflammatory host defense mechanisms against tumor cells. This view can even be further extended when taking the contribution of non-parenchymal CNS-associated macrophage populations (CAMS; also known as border-associated macrophages [Utz et al., 2020]) as well as potential differences of microglia subpopulations into account (Masuda et al., 2020). Based on our bulk and single-cell sequencing data it is tempting to speculate that dominant effects of tumor education could overwrite potential transcriptional differences in microglia subpopulations. Indeed, a previous study by Wingrove et al. did not observe differences in bulk sequencing data from BrM-associated stromal cells isolated from tumors at different anatomical sites within the brain (Wingrove et al., 2019). The heterogeneity of parenchymal and non-parenchymal CNS macrophage populations together with the influx of monocyte-derived macrophage populations into brain tumor lesions emphasizes the need for unbiased single cell analyses to capture the complexity of CNS inflammation in the context of different brain malignancies including brain metastasis. Moreover, the existence of distinct myeloid subpopulations as described, for example, in EAE in the brain (Jordao et al., 2019) or spinal cord (Giladi et al., 2020) could extend the spectrum of potential therapeutic targets.

Our data suggest that the complement system plays a central role in BrM-associated inflammation indicated by pronounced expression of different complement components in TAMs such as C1q and C3 in TAM-MG as well as C3ar1 in TA-Mono and TAM-MDM. Likewise, transcriptomes that indicate inflammation some activation (e.g., expression of Nlrp3 and Il1b) were evident in TAMs compared with normal microglia or monocytes. Both pathways are expected to modulate tumor immunity in multiple ways including the regulation of immune responses (e.g., by opsonizing tumor cells) as well as enhancing inflammation by further increasing the permeability of the blood-brain barrier (BBB) or BTB and additional recruitment of peripheral immune cells (Jacob and Alexander, 2014; Khan et al., 2015). However, the production of pro-inflammatory mediators such as C1q, IL1β, or TNF-α is expected to induce neurotoxic effects likely with the involvement of other cell types such as astrocytes (Liddelow et al., 2017). Therefore, future functional studies should address the question whether the induction of pro-inflammatory signatures in TAM-MG reflects an anti-tumor immune response or rather represents stromal cooption by the tumor cells in which host defense mechanisms are exploited to foster brain metastatic colonization and outgrowth as previously demonstrated (Chuang et al., 2013).

Synergistic effects of TME-targeted therapies in combination with standard of care including chemo- and radiotherapy represent a frequently observed phenomenon (Ding et al., 2019). Here we focused our analysis on the effects of WBRT on myeloid cells in BrM. Although immune-modulating effects of radiotherapy were neglected for a long time, recent studies established a link between ionizing radiation and the induction of pro-inflammatory responses that were shown to synergize with immunotherapies (Vanpouille-Box et al., 2017). As part of our study we sought to evaluate if WBRT could be used as an immune modulatory
agent to revert immunosuppressive TAM functions. We found that WBRT further enhances the recruitment of myeloid cells from the periphery. This effect was more pronounced in response to 5 × 2 Gy WBRT compared with 1 × 10 Gy WBRT. The observed differences at early time points upon irradiation can at least in part be explained by a higher degree of genotoxicity of single high doses on radio-sensitive blood-borne myeloid cells, dose-dependent differences in the impairment of the BBB/BTB, or different profiles of secreted cytokines. Although the recruitment of blood-borne cells was stronger after classically fractionated WBRT, single high doses induced more pronounced effects on gene expression changes based on the number of DEGs. Moreover, single high doses might have a greater potential to enhance pro-inflammatory responses compared with classically fractionated regimens.

Taken together, our data support the applicability of IR as an immune modulator. Given the cell type and dose-dependent differences of radio-responses, it will be critical to evaluate the optimal regimen for the desired outcome (e.g., rate of recruitment versus transcriptomic changes) for individual tumor types. Importantly, our data indicate that IR has the potential to transiently lift the immunosuppressive capacity of TAM-MDM either by direct effects on the TAM-MDM population or by enhancing the recruitment of tumor- and treatment-naive monocytes/macrophages to the CNS that have not yet acquired tumor education signatures. Single-cell RNA-seq analyses suggest that irradiated TAM-MDM represent a more heterogeneous population than TAM-MG, which could be due to the infiltration of naive monocytes/macrophages that replenish the cell pool. However, regardless of the underlying mechanism, reversion of immune suppression could be exploited to transiently generate a milieu that allows for higher efficacy of TME-targeted or immuno-therapies that are otherwise blunted by the immune-suppressive BrM environment.

In summary, our data represent a comprehensive resource on transcription profiles of different tumor-associated myeloid cells during BrM progression and in response to radiotherapy. Differences of transcriptional states in TAMs underscore the importance of detailed mechanistic insight in order to develop therapeutic strategies that target tumor-promoting functions with minimal risk in inducing adverse effects by either blocking physiologically important functions or inducing neurotoxic tissue damage within the CNS. Further investigation of patient BrM will be required to evaluate to which extent the pre-clinical data can be translated into the clinical situation.

Limitations of the Study
In this study, cellular and molecular changes in the myeloid cell compartment were characterized using the xenograft lung to brain metastasis model H2030-BrM. The aim was to examine effects of tumor progression and ionizing radiation on transcriptomic profiles of BrM-associated immune cells. Although we focused our analysis on the myeloid cell compartment as the most abundant immune cell population in brain metastases, it has to be acknowledged that the lack of mature T cells in the immunocompromised Athymic nude mice and potential incompatibilities of human cytokines and murine cytokine receptors can affect myeloid cell biology and thereby alter transcriptomic profiles in myeloid cells. Follow-up studies using different syngeneic and xenograft brain metastasis models are underway to address the question of lymphoid-myeloid cross talk in brain metastasis and to evaluate the degree of T cell-mediated effects on myeloid cells in brain metastases. Moreover, future studies will be critical to evaluate the generalizability of the findings described herein based on one model and broaden the knowledge on core transcriptomic profiles of TAMs in BrM derived from different primary tumor entities that metastasize to the brain. In this context it will be important to include spontaneous BrM models to study the effects of the primary tumor on monocyte trafficking to the brain and its impact on TAM phenotypes in BrM. Given the complication of choosing the optimal marker combination to discriminate different myeloid subpopulations without using lineage tracing models, single cell-omics techniques will become indispensable to fully capture the complexity of the cellular composition and transcriptional repertoire of the BrM TME.

Resource Availability
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lisa Sevenich (sevenich@gsh.uni-frankfurt.de).

Materials Availability
This study did not generate new unique reagents.
Data and Code Availability

Tables S1 and S2 provide direct access to the main results derived from transcriptomic analysis presented in this study. In addition, all sequencing data have been deposited to the Gene Expression Omnibus (GEO) under the superseries accession number GSE137797. Single-cell RNA-seq data can be found under GSE137512. All bulk RNA-seq data are deposited under GSE137762.

METHODS

All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101178.

ACKNOWLEDGMENTS

We thank Petra Dinse, Annette Trzmiel, Julius Oppermann, Stephanie Hehlgans, Jeannie Peifer, Judith Bergs, Sophie Giess, and Ewelina Czlonka for excellent technical support and members of the Sevenich lab and the Georg-Speyer-Haus for insightful discussion. We thank Joan Massague for providing the H2030-BrM cell line. Research in the lab of L.S. is supported by institutional funds from the Georg-Speyer-Haus jointly funded by the German Federal Ministry of Health and the Ministry of Higher Education, Research and the Arts of the State of Hesse (HMWK), as well as grants from the LOEWE Center Frankfurt Cancer Institute (FCI), the German Cancer Consortium (DKTK partner site Frankfurt/Mainz), the German Cancer Aid (Max-Eder Junior Group Leader Program 7011752), German Research Foundation (SE2234/3-1), and the Beug Foundation for Metastasis Research.

AUTHOR CONTRIBUTIONS

M.S. and L.S. designed all experiments, M.S. performed most of the experiments and bioinformatic analyses, B.M. and H.F. assisted in the bioinformatics analysis, K.N. and S.S. assisted in the flow cytometric analysis, F.R. assisted and advised on the application of radiotherapy, and M.S. and L.S. wrote the manuscript. L.S. conceived and supervised the project. All authors edited and commented on the manuscript.

DECLARATION OF INTERESTS

The authors declare no conflict of interest.

REFERENCES

Ajami, B., Samusik, N., Wieghofer, P., Ho, P.P., Crotti, A., Bjornson, Z., Prinz, M., Fanit, W.J., Nolan, G.P., and Steinman, L. (2018). Single-cell mass cytometry reveals distinct populations of brain microglial cells in mouse neuroinflammation and neurodegeneration models. Nat. Neurosci. 21, S41–S51.

Albulescu, R., Codrici, E., Popescu, I.D., Mihai, S., Necula, L.G., Petrescu, D., Teodoru, M., and Tanase, C.P. (2013). Cytokine patterns in brain tumour progression. Mediators Inflamm. 2013, 979748.

Bennett, M.L., Bennett, F.C., Liddelow, S.A., Ajami, B., Zamanian, J.L., Fernhoff, N.B., Mulinyawe, S.B., Bohlen, C.J., Adil, A., Tucker, A., et al. (2016). New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. U S A 113, E1736–E1746.

Betancur, P.A., Abraham, B.J., Yiu, Y.Y., Willingham, S.B., Khameneh, F., Zareegar, M., Kuo, A.H., McKenna, K., Kojima, Y., Leeper, N.J., et al. (2017). A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat. Commun. 8, 14802.

Bouwens van der Vlis, T.A.M., Kros, J.M., Mustafa, D.A.M., van Wijck, R.T.A., Ackermans, L., van Hagen, P.M., and van der Spek, P.J. (2018). The complement system in glioblastoma multiforme. Acta Neuropathol. Commun. 6, 91.

Bouwens van der Vlis, T.A.M., Kros, J.M., Mustafa, D.A.M., van Wijck, R.T.A., Ackermans, L., van Hagen, P.M., and van der Spek, P.J. (2018). The complement system in glioblastoma multiforme. Acta Neuropathol. Commun. 6, 91.

Bowman, R.L., Klemm, F., Akkar, L., Pyonteck, S.M., Sevenich, L., Quail, D.F., Dhara, S., Simpson, K., Gardner, E.E., Iacobuzio-Donahue, C.A., et al. (2016). Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 17, 2445–2459.

Butovsky, O., and Weiner, H.L. (2018). Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 19, 622–635.

Cassettà, L., and Pollard, J.W. (2018). Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17, 887–904.

Chae, W.H., Niesel, K., Schulz, M., Klemm, F., Joyce, J.A., Prummer, M., Brill, B., Bergs, J., Rodel, F., Pilatus, U., and Sevenich, L. (2019). Evaluating magnetic resonance spectroscopy as a tool for monitoring therapeutic response of whole brain radiotherapy in a mouse model for breast-to-brain metastasis. Front. Oncol. 9, 1324.

Chen, Z., Feng, X., Herting, C.J., Garcia, V.A., Nie, K., Pong, W.W., Rasmussen, R., Dwiwi, B., Seby, S., Wolf, S.A., et al. (2017). Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. 77, 2266–2278.
Chuang, H.N., van Rossum, D., Sieger, D., Siam, L., Klemm, F., Bleckmann, A., Bayerova, M., Farhat, K., Scheffel, J., Schulz, M., et al. (2013). Carcinoma cells misuse the host tissue damage response to invade the brain. Glia 61, 1331–1346.

Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., and Amit, I. (2018). Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 172, 1073–1081.

Ding, A.S., Routekivitch, D., Jackson, C., and Lim, M. (2019). Targeting myeloid cells in combination treatments for glioma and other tumors. Front. Mol. (2019). Targeting myeloid cells in combination treatments for glioma and other tumors. Front. Mol. Immunol. 10, 1715.

Giladi, A., Wagner, L.K., Li, H., Dorr, D., Medaglia, C., Paul, F., Shemer, A., Jung, S., Yona, S., Mack, M., et al. (2020). Cxcl10(+) monocytes define a pathogenic subset in the central nervous system during autoimmune encephalomyelitis. Nat. Immunol. 21, 525–534.

Hagemeyer, N., Hanft, K.M., Akridtou, M.A., Unge, N.P., Bublitz, E.R., Staszel, O., Dimou, L., and Prinz, M. (2017). Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. Acta Neuropathol. 134, 441–458.

Jacob, A., and Alexander, J.J. (2014). Complement and blood-brain barrier integrity. Mol. Immunol. 61, 149–152.

Jakov, S., and Dimou, L. (2017). Glial cells and their function in the adult brain: a journey through the history of their ablation. Front. Cell Neurosci. 17, 24.

Jordao, M.C.J., Sankowski, R., Brendecke, S.M., Sagar, Locatelli, G., Tai, Y.H., Tay, T.L., Schramm, E., Armbruster, S., Hagemeyer, N., et al. (2019). Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 365, eaat7554.

Kalsi, R., Feigenberg, S., Kwok, Y., Tkaczuk, K., Mehta, M., and Chumsri, S. (2015). Brain tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 349, aad3018.

Kozakiewicz, L., Williamson, J., and Shaft-Zagardo, B. (2017). Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposure. Glia 65, 2051–2069.

Quail, D.F., and Joyce, J.A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437.

Ray, A.K., DuBois, J.C., Gruber, R.C., Guzik, H.M., Guinelli, M.E., Perumal, G., Raine, C., Kozakiewicz, L., Williamson, J., and Shaft-Zagardo, B. (2017). Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposure. Glia 65, 2051–2069.

Sankowski, R., Bottcher, C., Masuda, T., Geirsdottori, L., Sagard, S., Seredenina, T., Mahler, C., Wang, J., and Prinz, M. (2020). Microglia heterogeneity in the single-cell era. Cell Rep. 30, 1271–1281.

Chuang, H.N., van Rossum, D., van Rossum, D., Sieger, D., Siam, L., Klemm, F., Bleckmann, A., Bayerova, M., Farhat, K., Scheffel, J., Schulz, M., et al. (2013). Carcinoma cells misuse the host tissue damage response to invade the brain. Glia 61, 1331–1346.

Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., and Amit, I. (2018). Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 172, 1073–1081.

Ding, A.S., Routekivitch, D., Jackson, C., and Lim, M. (2019). Targeting myeloid cells in combination treatments for glioma and other tumors. Front. Mol. (2019). Targeting myeloid cells in combination treatments for glioma and other tumors. Front. Mol. Immunol. 10, 1715.

Giladi, A., Wagner, L.K., Li, H., Dorr, D., Medaglia, C., Paul, F., Shemer, A., Jung, S., Yona, S., Mack, M., et al. (2020). Cxcl10(+) monocytes define a pathogenic subset in the central nervous system during autoimmune encephalomyelitis. Nat. Immunol. 21, 525–534.

Hagemeyer, N., Hanft, K.M., Akridtou, M.A., Unge, N.P., Bublitz, E.R., Staszel, O., Dimou, L., and Prinz, M. (2017). Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. Acta Neuropathol. 134, 441–458.

Jacob, A., and Alexander, J.J. (2014). Complement and blood-brain barrier integrity. Mol. Immunol. 61, 149–152.

Jakov, S., and Dimou, L. (2017). Glial cells and their function in the adult brain: a journey through the history of their ablation. Front. Cell Neurosci. 17, 24.

Jordao, M.C.J., Sankowski, R., Brendecke, S.M., Sagar, Locatelli, G., Tai, Y.H., Tay, T.L., Schramm, E., Armbruster, S., Hagemeyer, N., et al. (2019). Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 365, eaat7554.

Kalsi, R., Feigenberg, S., Kwok, Y., Tkaczuk, K., Mehta, M., and Chumsri, S. (2015). Brain metastasis and response to ado-trastuzumab emtansine (T-DM1) in breast cancer: a case report and literature review. Clin. Breast Cancer 15, e163–e166.

Keren-Shaul, H., Spink, A., Weiner, A., Matcovitch-Natan, O., Dvor-Szternfeld, R., Ulland, T.K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017). A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290.e1.

Khan, M.A., Assiri, A.M., and Broering, D.C. (2015). Complement and macrophage cross talk during process of angiogenesis in tumor progression. J. Biomed. Sci. 22, 58.

Krasemann, S., Madore, C., Calic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017). The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581.e9.

Liddelow, S.A., Guttenplan, K.A., Clarke, L.E., Belcher, A.D., BoATEGORIES, C.J., Schirmer, L., Bennett, M.L., Munch, A.E., Chubb, W.S., Fishman, J.C., et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487.
Valiente, M., Ahluwalia, M.S., Boine, A., Brastianos, P.K., Goldberg, S.B., Lee, E.Q., Le Rhun, E., Preusser, M., Winkler, F., and Soffietti, R. (2018). The evolving landscape of brain metastasis. Trends Cancer 4, 176–196.

Valiente, M., Obenauf, A.C., Jin, X., Chen, Q., Zhang, X.H., Lee, D.J., Chaft, J.E., Kris, M.G., Huse, J.T., Brogi, E., and Massague, J. (2014). Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002–1016.

Van Hove, H., Martens, L., Scheyltjens, I., De Vlaminck, K., Pombo Antunes, A.R., De Prijck, S., Vandamme, N., De Schepper, S., Van Isterdael, G., Scott, C.L., et al. (2019). A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 22, 1021–1035.

Vanpouille-Box, C., Alard, A., Aranyakayil, M.J., Sarfraz, Y., Diamond, J.M., Schneider, R.J., Inghirami, G., Coleman, C.N., Formenti, S.C., and Demaria, S. (2017). DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618.

Wilkins, A.C., Patin, E.C., Harrington, K.J., and Melcher, A.A. (2019). The immunological consequences of radiation-induced DNA damage. J. Pathol. 247, 606–614.

Wingrove, E., Liu, Z.Z., Patel, K.D., Arnal-Estape, A., Cai, W.L., Melnick, M.A., Politi, K., Monteiro, C., Zhu, L., Valiente, M., et al. (2019). Transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis. Cell Rep. 27, 1277–1292.e7.

Wong, J., Armour, E., Kazanzides, P., Iordachita, I., Tryggestad, E., Deng, H., Matrinfar, M., Kennedy, C., Liu, Z., Chan, T., et al. (2008). High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. Int. J. Radiat. Oncol. Biol. Phys. 71, 1591–1599.

Yang, M., McKay, D., Pollard, J.W., and Lewis, C.E. (2017). Neuronal cell-type classification: challenges, opportunities and the path forward. Nat. Rev. Neurosci. 18, 530–546.
Supplemental Information

Cellular and Molecular Changes of Brain Metastases-Associated Myeloid Cells during Disease Progression and Therapeutic Response

Michael Schulz, Birgitta Michels, Katja Niesel, Stefan Stein, Henner Farin, Franz Rödel, and Lisa Sevenich
Figure S1. Analysis of the TME in H2030-BrM, related to Figure 1. (A) Macroscopic images of BLI signal of a representative H2030-BrM bearing mouse and the corresponding photograph of the brain. (B) H&E stainings of brain sections with small (left) or large (right) H2030-BrMs. Scale bar depicts 1 mm. (C) Representative immunofluorescence image of proliferating cells within and adjacent to H2030-BrM lesions. Sections were stained for Iba1 to visualize microglia/macrophages (red) and the proliferation marker Ki67 (green). Scale bar; 50 μm. (D) Representative gating strategy for flow cytometry and cell sorting for (BrM-bearing) brain (i) and blood monocytes (N-Mono) isolated from peripheral blood (ii). (E) Quantification of RNA-Seq data showing expression levels of distinct cell-type specific genes to validate the purity of sorted cell populations. (F) PCA plot of BrM-associated cells in small vs. large BrM. TA = tumor-associated. n=4 for TA-Mono and TA-Granu from small BrM and n=5 for all other groups.
Figure S2. Tumor education signatures in TAMs, related to Figure 2. (A) Selected up- (red) or down (blue) regulated common genes in tumor-associated myeloid populations compared to normal controls and plot of the top 5 corresponding functional pathways. (B-D) Validation of candidate genes by qRT-PCR. Gene expression of selected genes that show differential expression in (A) TAM-MG relative to N-MG (B) TAM-MDM relative to N-Mono and (C) TA-Mono relative to N-Mono. n=2 for all conditions and analyzed genes apart from Apoe in TAM-Mono with n=1. Data are represented as mean of RQ values ± RQ min and max.
Figure S3. TAM-MG display similarities to DAMs, related to Figure 3. (A) Expression of homeostatic microglia marker in TAM-MG and TAM-MDM. (B) Expression of typical disease-associated microglia marker (derived from Keren-Shaul et al., 2017) in TAM-MG; for A and B: Values are derived from variance-stabilized data (vst (≈ log2)) of RNA-Seq data from the comparison control (N-MG or N-MONO, each n = 4) vs. TAM-MG/TAM-MDM (each in total n = 10). Significance based on padj values, with *P<0.05, **P<0.01 and ***P<0.001, ns = not significant.
Figure S4. H2030 Tumor cells upregulate CD47 in vicinity to Iba1 positive cells, related to Figure 3. (A) Representative immunofluorescence images of H2030-BrM in vitro and H2030-BrM lesions in vivo stained for Iba1 (white) to visualize microglia/macrophages and CD47 (red). Tumor cells are stained for GFP (green). Arrows indicate CD47+ tumor cells in close vicinity to Iba1+ TAMs. Scale bar depicts 50 µm. (B) Quantification of relative expression levels of Tnf in comparison to CTRL cells (N-MG or N-Mono) vs. BrM-associated cells (small and large) (TA-Mono, TAM-MDMs, or TAM-MGs) based on values of variance-stabilized data (vst (≈ log2)) of RNA-Seq data. N-Mono: n=4, N-MG: n=4, small BrM-associated TA-Mono: n=4, all other groups: n=5. P values are based on padj, ***P<0.001
Figure S5. Transcriptomic profiles of irradiated TAM-MG and TAM-MDM, related to Figure 5. (A) Heatmap (left) and list (right) of the 66 differentially expressed “Slc“-family members in N-MG (n=4) vs. TAM-MG (small and large stage BrM, n=5 for each condition), cutoff: BM >20, adj. p<0.05. (B) Venn diagram displaying the number of DEGs (cutoff: BM >20) of RNA-Seq data comparisons between controls (N-Mono or N-MG, n=4) with either large stage TAM-MDM or TAM-MGs (n=5), or samples ten days after WBRT (n=3). (C-D) Venn diagrams of (C) TAM-MG and (D) TAM-MDM. Comparison of RNA-Seq data of large stage (n=5) BrM samples vs. WBRT (5x2 Gy/d3 and d5 n=4, 1x10 Gy/d3 and 5x2 Gy/d10 n=3). (E) Unsupervised hierarchical clustering heatmap depicting the Top 100 DEGs in N-MG vs. TAM-MG/D3 (5x2 Gy) including irradiated N-MG at d3 upon 5x2 Gy, as well as TAM-MG at d3 upon 1x10 Gy WBRT.
Figure S6. Single cell RNAseq reveals heterogeneous TAM populations, related to Figure 6. (A) Correlation plot depicting clustering of the analyzed cells of each experimental condition. (B) Number of mean detected genes per cell and the cell number used for analysis across all experimental groups. (C-E) List of up- and downregulated marker genes for indicated clusters, with corresponding functional gene annotation for cluster 13 and 14 (E), with up- (red) and downregulated (blue) genes for selected clusters. A maximum of five pathways is represented.
Table S3. List of antibodies, Related to Figure 1, Figure 3, Figure 4, Figure S1, Figure S4

**Antibodies used for histology**

| Antigen  | Host  | Clonality / Clone    | Dilution | Vendor                | Cat No   |
|----------|-------|----------------------|----------|-----------------------|----------|
| C1q      | rat   | monoclonal / 7H8     | 1:100    | abcam                 | ab11861  |
| C3/C3a   | chicken | polyclonal          | 1:200    | abcam                 | ab48581  |
| C3ar1    | rat   | monoclonal / 14D4    | 1:1,000  | Hycult Biotech        | HM1123   |
| CD47     | rat   | monoclonal / miap301 | 1:200    | Thermo Fisher Scientific | 50-126-11 |
| Collagen-IV | rabbit | polyclonal        | 1:200    | Merck                 | AB756P   |
| Factor H | sheep | polyclonal          | 1:500    | abcam                 | Ab8842   |
| Gfap     | goat  | polyclonal          | 1:1,000  | abcam                 | ab53554  |
| GFP      | chicken | polyclonal        | 1:1,000  | abcam                 | ab13970  |
| Iba1     | rabbit | polyclonal          | 1:1,000  | Wako Chemicals        | 019-19741 |
| Ki67     | rat   | monoclonal / SolA15 | 1:500    | Thermo Fisher Scientific | 50-245-563 |
| Ly6G     | rat   | monoclonal / RB6-8C5 | 1:200    | abcam                 | ab25377  |
| NeuN     | rabbit | monoclonal / EPR12763 | 1:10,000 | abcam                 | ab177487 |
| Tmem119  | guinea pig | polyclonal         | 1:1,000  | sysy                  | 400004   |

**Antibodies used for flow cytometry**

| Antigen | Host | Clone | Fluorochrome | Dilution | Vendor         | Cat No |
|---------|------|-------|--------------|----------|----------------|--------|
| CD11b   | rat  | M1-70 | BV605        | 1:1,000  | BD             | 563015 |
| CD45    | rat  | 30-F11| A700         | 1:500    | Biolegend      | 103128 |
| CD49d   | rat  | R1-2  | Pe-Cy7       | 1:500    | Biolegend      | 103618 |
| Ly6C    | rat  | HK1.4 | PerCP-Cy5.5  | 1:250    | Biolegend      | 128012 |
| Ly6G    | rat  | 1A8   | BV421        | 1:500    | BD             | 562737 |
TRANSPARENT METHODS

Mice

All animal studies were approved by the government committee (Regierungspräsidium Darmstadt, Germany) and were conducted in accordance with the requirements of the German Animal Welfare Act. Athymic/nude mice (CAnN.Cg-Foxn1nu/Crl) were purchased from Charles River Laboratories or bred within the GSH animal facilities. Six to eight-week old females were used for experiments with brain metastatic mice and RNAseq analysis. For qRT-PCR validation female and male mice were used.

Cell lines

Brain metastatic (BrM) variants of the human lung cancer cell line H2030 (here denoted as H2030-BrM) were provided by Dr. Joan Massagué, MSKCC, and labeled with a triple-imaging vector (TK-GFP-Luc; TGL) to allow for non-invasive in vivo imaging of tumor growth over time. H2030-BrM cells were cultured in RPMI 1640 medium supplemented with 10 % FBS, 2mM L-Glutamine and 100 units/ml penicillin-streptomycin.

Secretome Analysis of H2030

Secreted factors present in H2030 supernatant were determined using a human multiplex cytokine assay (BioRad, Ca, USA) according to the manufacturer’s instructions and analyzed on a Bioplex200 (BioRad). Complete RPMI media was used as reference control. The Bioplex-Manager software (v. 6.1) was used for acquisition of raw data. Data were obtained from three biological replicates.

Generation of experimental brain metastasis and in vivo BLI measurements

Generation of experimentally induced BrM was performed as previously described (Bos et al., 2009). Mice were anesthetized with ketamine / xylazine and 5x10^4 cells in 100 µl 1x PBS were inoculated into the left ventricle of 6 to 8-week old Athy/nu mice (intra-cardiac injection = i.c.). Starting 3 weeks after i.c. injection, BrM progression was monitored weekly via bioluminescence imaging (BLI) (Caliper Life Sciences, Ivis Lumina II), following subcutaneous injection of 100 µl luciferin (15 mg/ml). Mice were anesthetized with isoflurane (2%) during the measurement. For
further experiments, animals were stratified into groups based on BLI-values (radiance = $p/s/cm^2/sr$) showing an BLI output range of $5 \times 10^5$ to $7.5 \times 10^7$ for small, or $1 \times 10^6$ to $5.3 \times 10^8$ photons x sec$^{-1}$ for large BrM lesions, respectively.

**RNA isolation, cDNA synthesis and quantitative real-time PCR**

RNA from bulk sorted cell populations was isolated with Trizol LS, resuspended in DEPC-treated water, and 0.5 - 1 $\mu$g of RNA was used for cDNA synthesis. The following Taqman assays were used for qRT-PCR: Axl Mm00437221_m1, Apoe Mm01307193_g1, C3 Mm01232779_m1, C3ar1 Mm02620006_s1, Ctsb Mm01310506_m1, Hif1a Mm00468869_m1, Il1b Mm00434228_m1, Irf7 Mm00516793_g1, Nlrp3 Mm00840904_m1, P2rx4 Mm00501787_m1, P2ry12 Mm01950543_s1, Vegfa Mm00437306_m1, Zbp1 Mm01247052_m1. Assays have been run in triplicate and expression was normalized to Ubiquitin C ($Ubc$ Mm02525934_g1) for each sample.

**Whole Brain Radiotherapy**

For Whole Brain Radiotherapy, mice were stratified into different groups based on BLI output. Radiotherapy was applied on d0 with the Small Animal Radiation Research Platform (SARRP, X-Strahl Ltd, Camberley, UK) (Wong et al., 2008) as previously described (Chae et al., 2019). The SARRP is equipped with an on-board Cone Beam CT (CBCT) system for diagnostic imaging and radiation treatment planning. The integrated Muriplan software allows contouring, image-guided treatment design, dose calculation and application of radiation. Mice were anesthetized with isoflurane (2.5 %), stabilized in the prone position and imaged by performing a CBCT operating at 60 kV and 0.8 mA. CBCT images were next transferred to the Murislice software and individual isocenters were selected for radiotherapy. Irradiation was applied as WBRT as fractionated doses with 2 Gy on 5 consecutive days or with a single dose of 10 Gy using a 10x10 mm collimator as 1 arc operating at 220 kV and 13 mA with 5.2 cGy sec$^{-1}$.

**Tissue preparation and immunostaining**

Tissue for frozen histology was fixed in 4% PFA overnight and subsequently transferred into 30% sucrose until the tissue was fully equilibrated. Tissues were then embedded in OCT (Tissue-Tek) and 5 $\mu$m cryostat tissue sections were used for subsequent analyses. Hematoxylin and eosin (H&E) staining was performed on an automated staining device (Leica Autostainer XL) in the
histology core facility of the GSH. For immunofluorescence, frozen sections were thawed and dried at room temperature and rehydrated. For standard staining protocols, tissue sections were blocked in 3% BSA + 0.1% Triton-X100 in PBS for 1 h at room temperature, followed by incubation with primary antibodies in 1.5% BSA overnight at 4°C or 2 h at room temperature. Primary antibody information and dilutions are listed in Table S3. Fluorophor-conjugated secondary antibodies were used at a dilution of 1:500 in 1.5% BSA in PBS for 1h at room temperature. DAPI was used as nuclear counterstain.

For histology on thick tissue sections, PFA-fixed brain samples were sliced in 350 µm thick sections using a Vibratome VT1200S (Leica). Brain slices were cleared using the X-Clarity tissue clearing system (Logos Biosystem). Tissue clearing was performed at 0.6 A for 3 h using the X-Clarity electrophoretic tissue clearing solution. Afterwards, unspecific protein binding was blocked with 3% BSA in PBS containing 0.1% Triton-X100 followed by incubation with primary antibodies (Table S3) for 24 h at room temperature and fluorophor-conjugated secondary antibodies (Jackson ImmunoResearch) were used at a dilution of 1:500 in 1.5% BSA in PBS overnight at room temperature. DAPI was used as nuclear counterstain.

**Microscopy and image analysis**

Thin-section immunofluorescence stainings were imaged using a Zeiss Axio Imager. M2 Fluorescence Microscope (Zeiss, Germany) using a 10, 20, or 40x objective. Immunofluorescence staining on cleared thick sections was visualized using the Yokogawa CQ1 confocal microscope (Yokogawa, Musashino, Japan) using a 10, or 20x objective.

**Flow cytometry and fluorescence activated cell sorting (FACS)**

For flow cytometry and cell sorting, mice were anesthetized with Ketamine/Xylazine. Blood was collected by cardiac puncture and animals were transcardially perfused with PBS. Brain metastases were macrodissected based on ex vivo BLI signal and dissociated using the Brain Tumor Dissociation Kit (Miltenyi). A single cell suspension was generated using the gentleMACS Octo dissociator. For non-tumor bearing controls, whole brain samples were dissociated. Cell suspensions were filtered through a 70 µm mesh filter followed by red blood cell lysis. Normal brain and brain metastases samples were incubated with Myelin Removal Beads (Miltenyi). Cell
suspensions were incubated for 5-10 min at 4°C with FC block followed by incubation with directly conjugated antibodies panels as well as eFluor-780 (live/dead-discrimination) for 15 min at 4°C. Antibodies for the flow panel can be found in the Table S3. All flow cytometry analyses were performed on a BD Fortessa device and FACS sorting was performed on a BD FACS Aria Fusion. Cells were sorted into 100 µl cold PBS. Samples were kept on ice until Trizol LS was added. Samples were frozen at -80°C for analyses of bulk populations. For single cell RNAseq, cells were sorted into pre-labelled 384 well plates and snap frozen on dry ice. Plates were stored at -80°C until further processing.

**RNA sequencing, gene expression analysis and data presentation**

RNA was isolated by chloroform extraction and isopropanol precipitation using a glycogen carrier. RNA-sequencing libraries were generated with the SMART-Seq preparation kit (CloneTech) and fragmented with the Nextera XT kit (illumina). Paired end, 150 base pair, sequencing was performed with an Illumina HiSeq2500. All steps were performed by Genewiz (New Jersey, USA). The following steps were performed as previously described (Michels et al., 2019). Pre-processing of fastq-files of bulk sequenced samples including filtering for quality scores, poly-A trimming, removal of N containing reads, artifact removal and clearing of rRNA contamination was achieved using a pipeline in the HUSAR platform, provided by DKFZ (Heidelberg, Germany). Transcriptomes were mapped to the mouse genome using the genecode annotations (release M12) and TopHat2 (v. 2.0.14) (Kim et al., 2013). The number of reads per gene was determined by HTSeq count. Overlaps were considered as unique. Further analysis was performed within R (v. 3.4.3), operating in RStudio (v. 1.1.453) with BioMart package (v. 2.34.1) and DESeq2 (v. 1.18.1) (Love et al., 2014). If not indicated otherwise, data for heatmaps and PCA-clustering were generated of variance-stabilized transformed data (which equals log2 transformation), respecting a BaseMean >20 and an adjusted p-value of 0.05 (= FDR 5 %). Data shown consist of 3 to 5 biological replicates per condition.

Original Euler plots were created with eulerr (v. 6.0.0). Venn-diagrams of selected data were created with Venny (v. 2.1; www.bioinfogp.cnb.csic.es/tools/venny/index.html) (Oliveros, 2015), and functional annotation of selected (top-) genes was done using Metascape (www.metascape.org) (Zhou et al., 2019). Un-/ and semi-supervised clustering and generation of
heatmaps was performed via manual selection of significant DEGs (base-mean >20 and padj <0.05 unless indicated otherwise), or TOP-X DEGs of variance-stabilized data. Heatmaps were processed in Heatmapper (http://www1.heatmapper.ca/expression) (Babicki et al., 2016) with default parameters, including Complete Linkage Clustering and Spearman Rank Correlation for distance measurement.

**Single Cell RNAseq**

RNA isolation, processing, reverse transcription, library preparation, and sequencing were performed based on the SORT-Seq protocol as previously described (Muraro et al., 2016). Quality control and data analysis was done with RaceID (Grun et al., 2016). Single cell RNA sequencing, quality control, raw data processing and analysis was performed by Single Cell Discoveries (SCD, Utrecht, Netherlands). Downstream analysis contained Poisson-corrected, UMI corrected raw mapped reads. For any further analysis, cells with an UMI >800 were used.

**Quantification and statistical analysis**

Summary data are presented as mean ± standard deviation, floating bars with lines indicating min, max and median or Tukey's box plots using GraphPad Prism software v7. Numerical data was analyzed using the statistical tests noted with the corresponding sections of the manuscript. Statistical analyses were performed with GraphPad Prism software v7 and R (version 3.4.3) performing tests as indicated and were considered statistically significant, with *P<0.05, **P<0.01 and ***P<0.001.

**SUPPLEMENTAL REFERENCES**

Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J. R., Maciejewski, A., and Wishart, D. S. (2016). Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res 44, W147-153.

Bos, P. D., Zhang, X. H., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., and Massague, J. (2009). Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009.

Chae, W. H., Niesel, K., Schulz, M., Klemm, F., Joyce, J. A., Prummer, M., Brill, B., Bergs, J., Rodel, F., Pilatus, U., and Sevenich, L. (2019). Evaluating Magnetic Resonance Spectroscopy as a
Tool for Monitoring Therapeutic Response of Whole Brain Radiotherapy in a Mouse Model for Breast-to-Brain Metastasis. Front Oncol 9, 1324.

Grun, D., Muraro, M. J., Boisset, J. C., Wiebrands, K., Lyubimova, A., Dharmadhikari, G., van den Born, M., van Es, J., Jansen, E., Clevers, H., et al. (2016). De Novo Prediction of Stem Cell Identity using Single-Cell Transcriptome Data. Cell Stem Cell 19, 266-277.

Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S. L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14, R36.

Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550.

Michels, B. E., Mosa, M. H., Grebbin, B. M., Yepes, D., Darvishi, T., Hausmann, J., Urlaub, H., Zeuzem, S., Kvasnicka, H. M., Oellerich, T., and Farin, H. F. (2019). Human colon organoids reveal distinct physiologic and oncogenic Wnt responses. J Exp Med 216, 704-720.

Muraro, M. J., Dharmadhikari, G., Grun, D., Groen, N., Dielen, T., Jansen, E., van Gurp, L., Engelse, M. A., Carlotti, F., de Koning, E. J., and van Oudenaarden, A. (2016). A Single-Cell Transcriptome Atlas of the Human Pancreas. Cell Syst 3, 385-394 e383.

Oliveros, J. C. (2015). Venny. An interactive tool for comparing lists with Venn diagrams.

Wong, J., Armour, E., Kazanzides, P., Iordachita, I., Tryggestad, E., Deng, H., Matinfar, M., Kennedy, C., Liu, Z., Chan, T., et al. (2008). High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 71, 1591-1599.

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., and Chanda, S. K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10, 1523.